Lombard Medical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported revenue of $3,044,000, operating loss of $6,765,000, loss before taxation of $7,583,000, net loss of $7,422,000 or $0.37 per basic and diluted share against revenue of $4,227,000, operating loss of $9,380,000, loss before taxation of $9,683,000, net loss of $8,460,000 or $0.45 per basic and diluted share a year ago. For the nine months, the company reported revenue of $9,769,000, operating loss of $21,378,000, loss before taxation of $23,919,000, net loss of $23,343,000 or $1.17 per basic and diluted share against revenue of $12,171,000, operating loss of $27,373,000, loss before taxation of $27,850,000, net loss of $26,199,000 or $1.54 per basic and diluted share a year ago. Net cash outflow from operating activities of $22,406,000 compared to $25,509,000 a year ago. Purchase of property, plant and equipment of $260,000 compared to $1,017,000 a year ago. The year-over-year reduction in global revenue is attributable to the redeployment of commercial resources from the US to Europe to support the launch of the Altura endovascular stent graft along with delayed stocking orders from the Company's Japanese distribution partner as it prepares for approval and launch of the IntelliFlex LP delivery system.